 |
市場調查報告書
商品編碼
2078195
黏多醣症(MPS) 治療市場：依療法、MPS 類型、最終使用者和地區分類Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, By MPS Type, By End User, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) |
||||||
預計到 2026 年，黏多醣症(MPS) 治療市場規模將達到 30.3 億美元，到 2033 年將達到 60.2 億美元。預計從 2026 年到 2033 年，該市場將以 10.3% 的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 30.3億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 10.30% | 2033年市場規模預測： | 60.2億美元 |
黏多醣症(MPS) 的治療主要著重於控制症狀、改善生活品質和延緩疾病進展。 MPS 是一組罕見的遺傳性疾病，其特徵是由於缺乏分解Glico(GAG) 的特定酶，導致 GAG 在細胞和組織中積聚。酵素替代療法 (ERT)：這是許多類型 MPS 的主要治療方法。 ERT 包括靜脈注射缺乏或不足的酶，以幫助分解積聚的 GAG。雖然 ERT 有益，但由於酵素可能無法有效穿過血腦障壁，因此可能無法有效治療神經系統症狀。造血幹細胞移植 (HSCT)：也稱為骨髓移植，HSCT 是一種將捐贈者的健康幹細胞移植到患者骨髓的治療方法。供體來源的細胞可以產生缺乏的酶，從而可能減少 GAG 的積聚。 HSCT 在疾病早期進行最為有效，此時尚未造成顯著且不可逆的損害。
市場動態
市場參與者正著力於多種非內部成長策略，包括針對黏多醣症(MPS) 治療的合作，預計這將推動全球黏多醣症(MPS) 治療市場的成長。例如，2021 年 9 月，致力於透過「韓特氏症為中心、以研究主導」的方式實現「更健康、更美好未來」的全球生物製藥公司武田藥品工業株式會社與全球專業製藥公司 JCR Pharmaceuticals 達成獨家合作及許可協議，共同開發 JR-141。 JR-141 是一種針對人類轉鐵蛋白受體和艾杜醣醛酸-2-硫酸酯酶 (IDS) 的新一代重組融合蛋白在臨床實驗藥物，用於治療亨特氏症候群。根據協議條款，武田將在加拿大、歐洲及其他地區（日本和亞太地區的部分國家和地區除外）銷售 JR-141。對於美國以外的這項授權合約，JCR 公司有權獲得一筆預付款，以及用於進一步開發和商業化的里程碑付款，並根據未來的銷售額獲得分級版稅。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數分析了全球黏多醣症(MPS) 治療市場的主要參與者：公司概況、產品系列、主要亮點、財務績效和策略。
- 全球黏多醣症(MPS) 治療市場報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用分析全球黏多醣症(MPS) 治療市場中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期新藥上市
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
第4章：全球黏多醣症（MPS）治療市場
- 經濟影響
- 對供需的影響
第5章 全球黏多醣症（MPS）治療市場：依治療方法分類，2021-2033年
- 酵素替代療法
- 幹細胞療法
第6章 全球黏多醣症（MPS）治療市場：依MPS類型分類，2021-2033年
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- 其他（MPS-III 和 MPS-IX）
第7章 全球黏多醣症（MPS）治療市場：依最終使用者分類，2021-2033年
- 醫院
- 專科診所
- 其他
第8章 全球黏多醣症（MPS）治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- 公司簡介
- Takeda Pharmaceutical Company Limited
- BioMarin Pharmaceuticals, Inc.
- Ultragenyx Pharmaceutical Inc.
- Sarepta Therapeutics
- Abeona Therapeutics Inc.
- Eloxx Pharmaceuticals
- Esteve
- Immusoft Corporation
- Inventiva
- GC Pharma
- JCR Pharmaceuticals Co Ltd.
- RegenxBio Inc.
- Sangamo Therapeutics, Inc.
- Bioasis Technologies Inc.
- Paradigm Biopharmaceuticals Ltd.
第10章
- 參考
- 調查方法
Mucopolysaccharidosis (MPS) Treatment Market is estimated to be valued at USD 3.03 Bn in 2026 and is expected to reach USD 6.02 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.03 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.30% | 2033 Value Projection: | USD 6.02 Bn |
The treatment of Mucopolysaccharidosis (MPS) is primarily focused on managing symptoms, improving the quality of life, and slowing down the progression of the disease. MPS is a group of rare genetic disorders characterized by the accumulation of glycosaminoglycans (GAGs) in cells and tissues due to deficiencies in specific enzymes responsible for breaking down these complex sugars. Enzyme Replacement Therapy (ERT): This is the mainstay treatment for many types of MPS. In ERT, the missing or deficient enzyme is administered intravenously to help break down the accumulated GAGs. Although ERT can be beneficial, it may not effectively treat neurological symptoms because the enzyme may not efficiently cross the blood-brain barrier. Hematopoietic Stem Cell Transplantation (HSCT): Also known as bone marrow transplantation, HSCT involves transplanting healthy stem cells from a donor into the patient's bone marrow. The donor cells can produce the missing enzyme, leading to a potential reduction in GAG accumulation. HSCT is most effective when performed early in the disease course before significant irreversible damage has occurred.
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations for the treatment mucopolysaccharidosis (MPS), which is expected to boost the global mucopolysaccharidosis (MPS) treatment market growth. For instance, In September 2021, Takeda Pharmaceuticals, a patient-focused, R&D-driven, global biopharmaceutical company committed to bringing Better Health and a Brighter Future, entered into an exclusive collaboration and license agreement with JCR Pharmaceuticals is a global specialty pharmaceuticals company, to commercialize JR-141, an investigational next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome. Under the terms of the agreement, Takeda commercialized JR-141 outside of the U.S., including Canada, Europe, and other regions (excluding Japan and certain other Asia Pacific countries). JCR received an upfront payment for such an ex-US license and is eligible to receive additional development and commercial milestones, as well as tiered royalties on potential sales.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
- Global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market.
Detailed Segmentation:
- Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Revenue, USD Bn, 2021 - 2033)
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type (Revenue, USD Bn, 2021 - 2033)
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- Others (MPS-III and MPS-IX)
- Global Mucopolysaccharidosis (MPS) Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Others
- Global Mucopolysaccharidosis (MPS) Treatment, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited
- BioMarin Pharmaceuticals, Inc.
- Ultragenyx Pharmaceutical Inc.
- Sarepta Therapeutics
- Abeona Therapeutics Inc.
- Eloxx Pharmaceuticals
- Esteve
- Immusoft Corporation
- Inventiva
- GC Pharma
- JCR Pharmaceuticals Co Ltd.
- RegenxBio Inc.
- Sangamo Therapeutics, Inc.
- Bioasis Technologies Inc.
- Paradigm Biopharmaceuticals Ltd.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By MPS Type
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Mucopolysaccharidosis (MPS) Treatment Market
- Economic Impact
- Impact on Supply and Demand
5. Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
6. Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- MPS-I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-VI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- MPS-VII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Others (MPS-III and MPS-IX)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
7. Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
8. Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country/Region, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BioMarin Pharmaceuticals, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sarepta Therapeutics
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abeona Therapeutics Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eloxx Pharmaceuticals
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Esteve
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Immusoft Corporation
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Inventiva
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GC Pharma
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- JCR Pharmaceuticals Co Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RegenxBio Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bioasis Technologies Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paradigm Biopharmaceuticals Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
10. Section
- References
- Research Methodology
- About us and Sales Contact
黏多醣症治療市場規模、佔有率和成長分析：按黏多醣貯積症類型、療法、通路、最終用戶和地區分類－2026-2033年產業預測
赫勒氏症候群（第一型黏多醣症）：新型療法、未滿足的需求和TPP洞察報告，2026年賀勒氏症（第一型黏多醣症）：全球市場展望、流行病學、競爭格局與市場預測報告（32個主要市場），2025-2035年賀勒氏症（第一型黏多醣症）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）
全球黏多醣症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）黏多醣貯積症治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，預測（2026-2034 年）
黏多醣症治療市場報告：2031 年趨勢、預測與競爭分析